Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 1
2007 1
2008 1
2009 2
2010 1
2011 3
2012 3
2016 2
2017 3
2018 2
2019 1
2020 2
2021 1
2023 3
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M. Bringhen S, et al. Among authors: cafro am. Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30. Leukemia. 2018. PMID: 29479061 Free article. Clinical Trial. No abstract available.
Myeloma's multiple morphologies.
Cantoni S, Galitzia A, Mancini V, Cafro AM, Cairoli R. Cantoni S, et al. Among authors: cafro am. EJHaem. 2023 Nov 10;5(1):260-261. doi: 10.1002/jha2.813. eCollection 2024 Feb. EJHaem. 2023. PMID: 38406505 Free PMC article. No abstract available.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Cavo M, et al. Among authors: cafro am. Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30. Lancet Haematol. 2020. PMID: 32359506 Clinical Trial.
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, Wermke M, Souza AD, Kaufman JL, Cafro AM, Ocio EM, Doki N, Henson K, Trabucco G, Carrion A, Bender FC, Juif PE, Fessehatsion A, Fan L, Stonehouse JP, Blankenship JW, Granda B, De Vita S, Lu H. Raab MS, et al. Among authors: cafro am. Leukemia. 2023 Jun;37(6):1349-1360. doi: 10.1038/s41375-023-01883-3. Epub 2023 Apr 6. Leukemia. 2023. PMID: 37024520
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.
Zappaterra A, Civettini I, Cafro AM, Pezzetti L, Pierini S, Anghilieri M, Bellio L, Bertazzoni P, Grillo G, Minga P, Pioltelli ML, Ravano E, Sassone M, Viganò CV, Volpato EB, Gambacorti-Passerini C, Rossini S, Cairoli R, Crocchiolo R. Zappaterra A, et al. Among authors: cafro am. Blood Transfus. 2024 Jul;22(4):328-337. doi: 10.2450/BloodTransfus.667. Blood Transfus. 2024. PMID: 38315530 Free PMC article.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Furlan A, Cea M, Pavan L, Galli M, Clissa C, Mangiacavalli S, Cafro AM, Girlanda S, Patriarca F, Minotto C, Bertoldero G, Barilà G, Pascarella A, Lico A, Paolini R, Rabassi N, Pescosta N, Porrazzo M, De Sabbata G, Pompa A, Bega G, Cavallin S, Guidotti F, Marcatti M, Rupolo M, Belotti A, Gherlinzoni F, Zambello R. Furlan A, et al. Among authors: cafro am. Cancer Med. 2024 Apr;13(7):e7071. doi: 10.1002/cam4.7071. Cancer Med. 2024. PMID: 38558233 Free PMC article.
Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis.
Cavallaro G, Paris L, Stefanoni P, Pavoni C, Mangiacavalli S, Cartia CS, Pompa A, Cafro AM, Pioltelli ML, Pezzatti S, Crippa S, Rambaldi A, Galli M. Cavallaro G, et al. Among authors: cafro am. Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024049. doi: 10.4084/MJHID.2024.049. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 38882460 Free PMC article. No abstract available.
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.
Martino EA, Derudas D, Rossi E, Terlizzi S, Reddiconto G, Stefanoni P, Micozzi J, Mangiacavalli S, Zamagni E, Offidani M, Furlan A, Buda G, Lotti F, Liberatore C, Lazzaro A, Pepa RD, Bertuglia G, Barbieri E, Conticello C, De Magistris C, De Paoli L, Bongarzoni V, Cafro AM, Mele A, Benvenuti P, Cerchione C, Botta C, Antonioli E, Sgherza N, Aquino S, Mele G, Barilà G, Palmieri S, Annibali O, Bianco R, Febbo MA, Casaluci GM, Rago A, Fontana R, Farina F, Vigna E, Bruzzese A, Mancuso K, Nappi D, Morè S, Rivolti E, Califano C, Amendola A, Roccotelli D, Lombardo A, Citro A, Uccello G, Zambello R, Maggi A, Neri S, Monachesi M, Gozzetti A, Montefusco V, Brunori M, Cotzia E, Pietrantuono G, Quinto AM, Amico V, Di Renzo N, Coscia M, Galli M, De Stefano V, Petrucci MT, Neri A, Di Raimondo F, Morabito F, Musto P, Gentile M. Martino EA, et al. Among authors: cafro am. Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.286658. Online ahead of print. Haematologica. 2024. PMID: 39605207 Free article.
29 results